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 ■ INTRODUCTION
In addition to the vast knowledge already available in 
physiology, pathology and therapeutics, there are still some key 
areas lacking the global and equally spread advantages of health 
sciences. One of these areas is undoubtedly maternal and perinatal 
health. Although a significant improvement has been achieved 
worldwide during the last two decades with the focus provided 
by the United Nations’ Millennium Development Goals (1) and 
currently by the Sustainable Development Goals (2), the capacity 
for predicting the most prevalent and hazardous conditions affecting 
pregnancies, mothers and babies is still very limited. Without 
prediction, there is no prevention, the pillar for providing good 
public health. Therefore, generally speaking, there are no available 
options other than trying to perform an early diagnosis of those 
potentially harmful conditions, including preterm birth (PTB), 
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as preeclampsia, preterm birth, fetal growth restriction, and gestational diabetes mellitus, are complex syndromes 
with multiple underlying mechanisms related to their occurrence. Limited advances in maternal and perinatal health 
in recent decades with respect to preventing these disorders have led to new approaches, and “omics” sciences have 
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genomics, transcriptomics, and proteomics, as metabolites are the final result of the interactions of genes, RNAs 
and proteins. Considering the recent “boom” in metabolomic studies and their importance in the research agenda, 
we here review the topic, explaining the rationale and theory of the metabolomic approach in different areas of 
maternal and perinatal health research for clinical practitioners. We also demonstrate the main exploratory studies 
of these maternal complications, commenting on their promising findings. The potential translational application of 
metabolomic studies, especially for the identification of predictive biomarkers, is supported by the current findings, 
although they require external validation in larger datasets and with alternative methodologies.
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preeclampsia (PE), gestational diabetes mellitus (GDM), fetal 
growth restriction (FGR), maternal and fetal infections and other 
conditions possibly associated with severe maternal morbidities. 
However, early diagnosis is almost always more expensive and not 
truly available for a significant proportion of populations, especially 
those in low- and middle-income settings.
Considering all these aspects, the purpose of the current review 
is to summarize the already existing knowledge on technologies 
that possibly represent new frontiers and future tools for predicting 
maternal and perinatal conditions responsible for a significant 
burden of disease in women and children in the world. Metabolomic 
biomarkers are one of these new promising tools and deserve special 
attention due to their potentially important role in the management 
approach for such conditions in the near future.
 ■ METABOLOMICS AS PART OF OMICS 
TECHNOLOGIES
The study of the biological systems of an organism leads to 
the understanding of complex interactions between the genes, 
their products (RNAs, proteins, and metabolites) and many 
environmental factors that determine their functioning (3,4). The 
recent development of what is called systems biology enables the 
recognition of these integrative pathways. The field of systems 
biology is related to the capacity to identify thousands of biological 
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molecules and to establish their interactions using advances in 
bioinformatics, statistics, and high-throughput techniques of 
sample analysis. The “omics” sciences emerged from this concept 
of integrative analysis in the field of systems biology and includes 
genomics, for the study of a set of genes (genome); transcriptomics, 
for a set of RNAs (transcriptome); proteomics, for a set of 
proteins (proteome); and metabolomics, for a set of metabolites 
(metabolome), as shown in Figure 1.
The clinical importance of omics sciences arises from the 
innovative approach of the dynamic regulations of biological 
systems, which can be explored by both holistic and reductionist 
strategies (5). A reductionist strategy is the use of only one part of 
a complex system or only one hypothesis to build conclusions or to 
understand the determinants of the whole process. On the other hand, 
a holistic approach considers multiple interactions and complexities 
to elucidate the whole system. Prevalent maternal complications, 
such as PE, PTB, GDM or FGR, are commonly addressed using a 
reductionist approach. For instance, a woman with a short cervix is 
considered to have a higher risk for PTB, or a fetus with an estimated 
weight below the 10th percentile is considered growth restricted. The 
omics sciences enable discovery-driven studies with a holistic and 
hypothesis-free approach and may provide the key step forward in 
addressing complex research problems in maternal and perinatal 
health, decreasing bias and confounders (3,6-10).
Genomics
Genomics is the study of genes and their functions and 
demonstrates the gene codification for proteins that modulate 
biological systems. Therefore, genomics may be useful to determine 
the genetic predisposition for a particular disease, identifying the 
genes involved in its pathophysiology. Genomics studies are more 
commonly performed using the candidate gene approach, through 
which preselected genes are sequenced. The complex interactions of 
genes in the development of a pathologic phenotype and the presence 
of nongenetic factors limit the results of this approach. Regularly, 
there is not only one gene involved in the development of a disease 
but also groups of genes. Moreover, parts of a gene (locus) can be 
related to the development of the disease, while other parts might 
be related to its prevention, and the polymorphisms and mutations 
of genes can determine a wide variance in gene expression. The 
genome-wide sequencing techniques of the exome can demonstrate 
a more complete view of the genetic predisposition and establish 
individuals’ prognostics and treatment resistance (11,12).
The main potential limitations of genomics are high cost 
and uncertainty between gene codification and gene expression/
phenotype. Only a small portion of the whole genome will be 
translated, and there are several mechanisms and processes 
that control the expression of genes (methylation, acetylation, 
epigenetic mechanisms, imprinting, etc.). Therefore, having the 
gene codification for a disease does not mean it will develop.
Transcriptomics
The next step to understand the development of a disease would 
be the study of gene expression. Transcriptomics is a step-forward 
technique compared to genomics in terms of downscaling genetic 
predispositions. Transcriptomics determines mRNA expression 
using many techniques, such as microarray-based methods, which 
are used to measure mRNA transcript levels, and sequence-based 
Figure 1 - Omics science components of biological systems
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methods, such as serial analysis of gene expression (SAGE), cap 
analysis of gene expression (CAGE), massively parallel signature 
sequencing (MPSS) and RNA-Seq technology (13). RNA-Seq 
appears to be the most advantageous transcriptomics approach since 
it requires a small amount of RNA and is a more precise, “clean” 
(less background signal) and much lower-cost method considering 
the high-throughput technology (13). The expression of mRNA in 
a particular tissue can differ according to the timeframe observed. 
For instance, the expression of proinflammatory proteins during 
labor is different from that during other pregnancy periods (4,14). 
Therefore, it is possible to compare the expression of mRNA in a 
tissue using arrays with tens or hundreds of genes and determine 
down- or upregulation of the gene expression according to the level 
of mRNA (4). The overexpression of a gene at a given phase of 
the biological process related to the development of a particular 
pathologic condition can uncover key points of the physiopathology 
of the disease and potential targets for prevention and treatment.
Despite these benefits, transcriptomics faces similar limitations 
to genomics. There is a recent conceptual discussion against the 
traditional idea that the final products of our genes are mostly 
proteins: gene (DNA) → mRNA → protein (15). The main genome-
wide sequencing projects have targeted only long protein-coding 
mRNAs, given this classical interpretation. However, more recent 
studies have identified many other gene-encoded contributors 
as long noncoding RNAs that play different roles in biological 
systems and metabolic pathways but do not encode proteins (16,17). 
The various mechanisms that take part in the regulation of gene 
expression, such as chromatin remodeling, adenylation, elongation, 
splicing, editing, nuclear export, and degradation, may limit the 
unbiased recognition of all mechanisms between gene expression 
and the clinical phenotype (15). These mechanisms seem to be 
extremely complex, requiring more developed research techniques 
and new approaches for the study of biological systems (5,18,19).
Proteomics
Proteins are key instruments of biological systems, and 
their abnormalities can cause or be a consequence of organism 
dysfunctions. The study of the proteins contained in a sample 
is called proteomics, which basically includes identification 
and quantification (3). Proteomics is a promising approach that 
reflects genetic and environmental effects in the development of 
pathological conditions. According to an evolutionary hypothesis 
regarding protein function, there are some proteins involved in the 
various metabolic pathways of an organism and others related to 
gene regulation and expression, including intra- and extracellular 
signaling and the mechanisms of gene expression (20). The 
abundance of proteins required to perform such roles is different 
depending on the complexity of their functions. Contrary to what 
would be obvious, highly specialized biological processes do 
not require high protein availability. Moreover, protein activity 
can vary depending on many factors, such as the concentration 
of substrates and the presence of other coenzymes. Therefore, 
the abundance of proteins seems not to be a reliable parameter 
to address their function. In addition to proteomics limitations, 
isolating proteins from blood remains a difficult task, and there is 
no single reliable, accurate and reproducible method capable of 
obtaining all proteomes (20).
Metabolomics
The metabolic pathway comprises different biochemical 
reactions occurring in the intracellular or extracellular compartment. 
Metabolites are the substrates and products of these metabolic 
reactions, which require enzymes (proteins), minerals, vitamins, 
and other cofactors. Metabolomics is the study of the set of 
metabolites of an organism, identifying and quantifying them with 
higher sensitivity and more reliable reproducibility (21). The set of 
these small low-weight molecules is called the metabolome, which 
is a fingerprint of the metabolism at a given time (3,4,7). Therefore, 
it is possible to understand the metabolism at that moment or, 
depending on the sample, to understand the metabolism of days to 
months ago. The hairs, for example, are stable, contain endogenous 
compounds, and reflect environmental exposure for many months 
prior (22). Human metabolomic research emerged from previous 
experience with plants, microbes, and other less complex mammals 
after years of bioinformatics/statistics advances to address massive 
output data (3,4,7). Metabolomics in maternal and perinatal 
health may enable the identification of biomarkers related to 
maternal and perinatal complications and the understanding of the 
physiopathology of the most complex and prevalent diseases, such 
as PE, PTB, GDM, FGR, maternal/fetal infections and other severe 
maternal morbidities (10,23-25).
Advantages of metabolomics include its hypothesis-free and 
unbiased approach and the downstream result of gene expression, 
being the closest to the phenotype of the omics sciences. Different 
technologies have to be employed to identify and quantify fatty 
acids, bile acids, ketone bodies, amino acids, peptides, carnitines, 
carbohydrates, vitamins, xenobiotics, steroids, etc. The modalities 
generally used are gas chromatography-mass spectrometry (GC-
MS), liquid chromatography-mass spectrometry (LC-MS) and 
nuclear magnetic resonance (NMR) spectroscopy. GC-MS and LC-
MS can identify and quantify tens of thousands of metabolites at 
one time, creating substantial output data in mass spectrum format, 
as shown in Figure 2. Mass spectrometry consists of the following 
components: 1) Sample inlet, a system that differs between GC-MS 
and LC-MS; 2) Ion source that ionizes molecules of the sample; 3) 
Analyzer that separates molecules through a long tube under vacuum 
according to their mass and charge (using the mass-to-charge 
ratio – m/z or the time-of-flight method to discriminate different 
metabolites); 4) Ion detector that detects different metabolites with 
a sensitivity capable of differing isomeric molecules and measuring 
the quantity of ions converted into electrical signals. The more 
molecules that are present, the greater is the electrical signal; and 
5) Data analysis system matched to a computer that interprets the 
signal as a mass spectra data (3,5,9,25). The next step is to identify 
metabolites using their m/z values and to compare them with their 
corresponding molecules in a previously known library, namely, the 
Human Metabolome Database – www.hmdb.ca (26).
There are many different customizations when using 
metabolomic analytical methods, allowing better identification 
of a specific range of mass of molecules or metabolites with 
different solubilities (5,21). The advantages and disadvantages of 
each method should be considered according to the experimental 
objectives. NMR methods require minimal sample preparation, 
preserving the samples in their natural form and can identify 
metabolites in intact tissues (3-D tissues). However, NMR-
based metabolomics has lower sensitivity and requires a greater 
sample volume. Mass spectrometry-based methods (GC or LC-
MS) are usually used as complementary methods, depending on 
the molecular polarity (polar or nonpolar), sample solubility, and 
choice for targeted or untargeted metabolomic analyses (3,5,27). 
The untargeted approach means the study of the whole set of 
metabolites in a given sample, while the targeted approach refers 
to the identification of a specific group. The untargeted approach is 
normally employed to identify new potential predictor biomarkers, 
and a targeted approach is commonly used for validation analysis 
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to measure previously known metabolites in a given sample 
(3,9). Especially in untargeted studies, there is a high possibility 
of returning to the biochemical reactions and to the metabolic 
pathways with which the identified metabolites are involved. This 
approach would present an opportunity to address complex diseases 
that are related to different biological systems (inflammatory, 
metabolic, energetic, immunologic, etc.).
Tissues and samples for exploring metabolomics
The use of appropriate biological samples is a key issue in 
defining the experimental design for metabolomic experiments. 
Considering pregnancy and childbirth, the available biological 
tissues can come from the mother (plasma, urine, vaginal fluids, 
milk, and hair), the fetus/newborn (amniotic fluid, umbilical cord 
blood, plasma, urine, meconium, saliva and other fluids from the 
infant), or the placenta. The choice will depend upon each study 
and the investigating aim defined (3,10).
The most commonly used biological sample is plasma, which 
is easy to obtain and rich in proteins and metabolites. In biomarker 
discovery, the final goal is to characterize markers that could enable the 
early identification of high-risk conditions, and the obvious and most 
simple screening test would be a blood sample (3,10,23). However, 
many biomarkers are present in low concentrations in plasma, and 
its study can be optimized by choosing a biological sample closer to 
the disease process, especially in the discovery phase, where a great 
number of identified biomarkers can suggest relevant conditions and 
pathways involved in the studied diseases (10).
Urine is the second most studied biological sample for 
metabolomic assays; it is easy to obtain, noninvasive and, like 
blood, an integrative biofluid. However, the profiling of urine is 
challenging overall with a wide-ranging variation in metabolite 
concentrations and fluctuating dilutions due to urine volume 
alterations. Implementing appropriate statistical analysis methods 
are pivotal (28).
There is an opportunity for specific metabolomic approaches 
to study changes in samples closer to diseases or samples clearly 
influenced by or specific to pregnancy. Vaginal secretions have 
been studied to understand markers of labor and preterm labor, 
considering that they can represent changes occurring in the vagina, 
cervix and adjacent overlying fetal membranes (10,29). There are 
still challenges in choosing the best way to collect samples and 
in considering the influences of individual characteristics, protein 
variations and contamination from previous intercourse or bleeding.
Amniotic fluid (AF) is another potential target for studying 
metabolomics during pregnancy. Collection of AF depends on an 
invasive and specialized procedure early during gestation, with 
potential risks of miscarriage, infection, preterm labor, or bleeding; 
however, AF is considered to have the best predictive value of 
metabolic profiling for malformed fetuses (10,30-32). It can also 
be obtained during labor or prior to delivery, and the discoveries 
arising could justify and overcome potential risks (33). The use of 
cord blood has mostly been addressed in neonatal research, with 
great potential in perinatal asphyxia as a noninvasive method to 
investigate and understand different conditions in the neonate after 
delivery (34).
A very important limitation on the use of plasma and most other 
biofluids is that the metabolites found are greatly dynamic and 
influenced by diet and immune status; furthermore, one isolated 
sample may not reflect the actual profile. There are standard 
procedures for sample collection and storage that need to be 
respected to guarantee accurate results, and immediate processing 
and freezing are mandatory (3,35,36).
Figure 2 - Mass spectrometry spectrum – scheme of metabolite output data.
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An additional source for metabolomic studies, considering 
pregnancy and childbirth, is the placenta. There are, however, 
important considerations regarding how to sample and peculiar 
difficulties in managing and controlling for confounding factors 
such as route of delivery, duration of labor, sex of the baby, and the 
time between delivery and sampling and storage for diverse assays 
(37). The study of the placenta may play a relevant role in the 
discovery phase and might help elucidate the involved mechanism 
and pathophysiology of conditions complicating pregnancy.
The search for biomarkers that can possibly be identified 
in an easy source of tissue, with no risks during pregnancy, that 
are noninvasive to obtain and store and, most importantly, that 
are able to represent long-term metabolite profiles has motivated 
researchers over the years. Hair metabolomics can provide these 
advantages and has great potential, with recent interesting results 
for predicting FGR (22).
Preterm birth
PTB is defined as childbirth before 37 weeks of gestation, 
and the real mechanisms of the spontaneous onset of preterm 
labor/rupture of membranes involved in its occurrence are still 
unknown. Uterine distension, decidual hemorrhage, stress, 
autoimmune, infection, inflammation, environmental, behavioral 
and socioeconomic factors are some of the hypothetical remarkable 
conditions linked with PTB (38). The identification of risk 
factors related to PTB has been studied for decades, but the 
complexity and dynamism of PTB development seem to require 
a multifactorial approach (4). The attempt to identify biological 
and sociodemographic markers capable of identifying high-risk 
pregnant women still has not achieved reasonable results. The 
only new screening and intervention-based recommendation for 
PTB prevention discovered in the last two decades is the second-
trimester transvaginal measurement of cervical length and vaginal 
progesterone for women with a short cervix (39,40). Further studies 
on cervical remodeling and associated biomechanical mechanisms 
must be performed (41).
Compared to isolated biological markers, the metabolomic 
approach seems to be superior for demonstrating the organism 
function (3,4,24,25,38). In 2010, Romero and colleagues published 
a study evaluating metabolites from processed and stored AF (42). 
They identified women who had spontaneous preterm labor (PTL) 
with intact membranes and had been submitted to transabdominal 
amniocentesis to assess the microbial state of the amniotic cavity 
and/or fetal lung maturity in three facilities. According to their 
pregnancy outcomes, women were divided into three groups: 1) 
with PTL and delivery at term; 2) with PTL, with preterm delivery 
and without intra-amniotic inflammation/infection (IAI); 3) with 
PTL, preterm delivery and IAI. Using phase 1 to identify potential 
metabolites that could differ from subgroups and phase 2 to validate 
the results of discrimination, the authors demonstrated that the 
metabolic profile from AF achieved 96.3% and 88.5% accuracy for 
phase 1 and 2, respectively, to predict the subgroups. Moreover, 
they also showed differences in the presence of amino acids (AAs) 
and carbohydrates in the AF samples in the subgroups. The results 
can contribute to developing AF tests for PTB, to new interventions 
for high-risk populations or to understanding PTB syndrome.
Menon et al. selected 50 African American women who 
participated in the Nashville Birth Cohort and collected AF samples 
during labor: 25 with PTB (before 34 weeks, excluding pPROM) 
and 25 with full-term births (33). Approximately 350 metabolites 
were identified in the AF using LC/MS and GC/MS mass analyzers. 
The metabolites were categorized following their participation in 
different biochemical pathways, such as histidine, steroids, xanthine, 
acetaminophen, bile acids, fatty acids, detoxification of xenobiotics 
and cosmetic-formulation chemical metabolism. The mean 
predictive accuracy to discriminate PTB from full term was 90%, 
with 14.2% false negatives. Although the predictive performance 
of this set of metabolites deserves additional validation, valuable 
information regarding the possible relationship between maternal 
liver function and PTB was reported.
In general, the collection of AF is an invasive procedure, and its 
use for metabolomic analysis is usually reserved when amniocentesis 
is indicated for another purpose, especially in women with higher 
risk for spontaneous onset of preterm labor. The reasons must be 
taken into account to avoid sampling bias, such as risk for fetal 
malformation or intra-amniotic cavity infection. Graça et al. and 
Diaz et al. conducted metabolomic studies related to maternal and 
fetal outcomes, such as GDM, fetal malformations/chromosomal 
disorders, PTB and pPROM (32,43,45). Urine, blood and AF samples 
were collected from women at high risk for fetal malformations/
chromosomal disorders. Therefore, the different concentrations of 
allantoin, myo-inositol, alanine, citrate and 2-hydroxyisobutyrate 
identified in the PTB group might not be generalized.
More recently, Ghartey et al. conducted a nested case-control 
study inside a prospective cohort to identify cervicovaginal (CV) 
biomarkers related to spontaneous PTB (29). CV samples were 
collected at 20 weeks – 23 weeks + 6 days (first visit – V1) and 
24 weeks – 27 weeks + 6 days (second visit – V2) gestational 
age intervals. The CV metabolome was analyzed from 10 women 
who had spontaneous PTB and 10 women who had term births 
using ultra-performance liquid chromatography-tandem mass 
spectrometry (UPLC/MS) and GC/MS. More than 300 metabolites 
were identified in the CV samples, and women with PTB had a 
distinct CV metabolome compared with that in samples of women 
with term birth. Considering V1 samples, more than half of the 
identified AAs were decreased in PTB samples, and methyl-4-
hydroxybenzoate, an antimicrobial agent, was increased in the CV 
samples of women with term birth. Thus, an increased presence 
of sialic acid in CV samples of PTB women in V2 samples and 
downregulation of carbohydrates were identified. Sialic acid plays 
a role in immune function, specifically on viral entry into the cell. 
Therefore, there were remarkable differences in CV metabolic 
markers in women with PTB, enabling the study of some metabolic 
pathways related to PTB occurrences, such as cervicovaginal 
protein hydrolysis, inflammation, carbohydrate metabolism and 
viral/bacterial infection modulation. Metabolomic analyses can 
be performed using different technical approaches depending on 
the spectrum of metabolites to be identified. These differences 
can modify the sensitivity of metabolite identification. Thomas 
and colleagues conducted a metabolomic analysis to identify 
discriminatory metabolites in CV fluid in women with PTB and 
term birth (44). In this study, the identification of AAs, organic 
acids and fatty acids was prioritized, but the number of metabolites 
identified was much less than that in Ghartey’s study. No significant 
difference was noticed between the CV metabolites of women with 
PTB and term birth (44).
Nonetheless, the collection of AF during preterm and term 
labor brings up a discussion of what benefits each period of 
sample collection during pregnancy may provide and the possible 
confounders. There are insufficient data to clarify if different 
metabolomic profiles during preterm labor are related to the 
mechanisms of preterm labor determinism or to the proper maternal 
and/or fetal metabolism that is characteristic of each gestational 
age period (45,46). A longitudinal targeted metabolomic profile 
conducted by Lindsay and colleagues showed AAs, nonesterified 
fatty acids, polar lipids, tricarboxylic acid cycle intermediate 
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metabolic changes in healthy pregnancies (47). HPLC-MS, LC-MS 
and flow-injection mass spectrometry analyses of plasma samples 
demonstrated the variance in amino acid concentrations across three 
set points of pregnancy (at the first, second and third trimester). The 
sum of the nonbranched chain essential AAs and tricarboxylic acid 
cycle intermediates increases from the first to the third trimester, 
whereas free carnitine and acetylcarnitine decrease. The findings 
seem to be consistent with placental and fetal mediation of AAs 
during pregnancy, with energetic synthesis and nitrogen cycle 
changes due to anabolic and catabolic phenomena.
There are complex metabolic cycles mediating fetal 
development, pregnancy homeostasis, autoimmune regulation, and 
placental multiple functions. There are many options of samples, a 
period of collection and metabolomic analyzers to study preterm 
syndrome, and each one might result in innovative contributions 
(3,4). The collection of samples during the preclinical phase 
(asymptomatic women) may provide early identification of higher-
risk women as well as lightening trigger mechanisms of preterm 
labor. Another way to elucidate those triggering mechanisms is 
collecting samples during labor or from the neonates, demonstrating 
the resulting PTB metabolic profile (48-50). Multiethnic validation 
of current findings is required to move forward on preterm prediction 
and prevention. Therefore, international collaborative studies are 
essential, shortening the time and financial resources (38).
Fetal growth restriction
Intrauterine growth restriction is an obstetric disorder 
characterized by the failure of a fetus to achieve its growth 
potential (51). It has a multivariate etiology, which includes genetic 
factors, infections, or uteroplacental insufficiency (52,53). This 
pathological condition is part of a broad spectrum, composed of 
“Small for Gestational Age” (SGA) fetuses, which includes all 
fetuses whose weight is below the 10th percentile for gestational age 
from the reference ranges applied to the specific population or based 
on customized charts (51,54). Some of them are physiologically 
small (constitutional) and therefore are not associated with adverse 
outcomes (52,53). The incidence of FGR is approximately 4–8% 
in industrialized countries and 6–30% in low- and middle-income 
countries (55).
FGR is associated with perinatal complications such as 
prematurity, fetal death and chronic metabolic disease in adulthood, 
such as diabetes mellitus type 2, hypertension and metabolic 
syndrome (56). The prenatal detection of fetuses with FGR is 
still a challenge in daily obstetric practice, and among low-risk 
pregnancies, the detection rate is approximately 15% (56). Whereas 
birth weight is a determinant of mortality and neonatal morbidity, 
much interest has been raised by research on new and effective 
means for the early diagnosis and/or prediction of FGR and the 
improvement of the clinical management (53).
Some single parameters have been tested or, when combined, 
compose a multifactorial model. The isolated analysis of serum 
adiponectin in pregnant women between 11 and 13 weeks, 
performed by Nanda and colleagues in 2011, revealed the inability of 
that factor to predict FGR because the concentration of adiponectin 
was the same in both the group with and the group without FGR 
(57). In an analysis of a multifactorial model, a group in the United 
Kingdom tested the association of mean maternal blood pressure, 
nuchal translucency, chorionic gonadotropin, serum pregnancy-
associated plasma protein (PAPP-A), pulsatility index of the uterine 
arteries, placental growth factor (PlGF), placental protein 13, and 
disintegrin and metalloprotease 12 (ADAM12). This model showed 
a 73% detection rate for FGR, with a false positive rate of 10% 
(58). In a second analysis, associating the pulsatility index of the 
uterine arteries, average maternal blood pressure, PAPP-A, and 
PlGF, the group achieved a 52.3% detection rate of FGR, with 10% 
false positives (59). However, the main challenge of this analysis 
is the great influence imposed by the frequent coexistence between 
preeclampsia and FGR in their results (60).
More recently, a meta-analysis evaluating the predictive ability 
of uterine artery Doppler performed in the first trimester achieved a 
sensitivity of 39.2% for cases of FGR established early (61). In this 
search for effective screening tools to accurately identify women 
at the highest risk of FGR, metabolomics has emerged as a new 
science, seeking biomarkers that can compose a predictive model, 
which could provide early diagnosis of FGR, with a reduction in 
morbidity and neonatal mortality. These studies have evaluated the 
metabolomes of biofluids (urine and blood) or hair for comparison 
between fetuses with FGR and fetuses with adequate weight for 
gestational age.
In 2010, Horgan and colleagues studied venous cord blood 
from women exhibiting the delivery of a healthy singleton fetus 
and from women with a suspected diagnosis of SGA (birth weight 
below the 10th percentile for gestational age) (62). Parallel to this 
analysis, women at 15 weeks of gestation underwent the analysis 
of plasma samples. Forty women who delivered SGA babies were 
matched to 40 controls who had uncomplicated pregnancies. The 
metabolomics of both analyses showed 29 metabolites in very 
different concentrations between the comparison groups (adequate 
for gestational age vs SGA). Of these, 19 metabolites were identified 
as predictors of the model and applied to analyses of cord blood and 
maternal peripheral blood. In the latter case, the predictive model 
showed an area under the curve (AUC) of 0.9, which represents a 
robust predictive model of presymptomatic SGA (62).
Dessi and colleagues studied the urine metabolic profiles of 
neonates with FGR and compared them with controls to define 
the metabolic patterns associated with this pathological condition. 
They observed a higher concentration of metabolites such as myo-
inositol (also found by Barberini et al. (63), sarcosine, creatine, 
and creatinine in FGR neonates. An increase in these metabolites 
in the urine is observed in states of hypercatabolism, as is the case 
with fasting, and there is a lower level of protein synthesis (64). 
On the other hand, Maitre and colleagues found decreased levels 
of tyrosine, acetate, trimethylamine, and formate in maternal urine 
samples of the late first trimester (65). These molecules can play 
a role in carbohydrate and fat metabolism (acetate), function as 
precursors of neurotransmitters (tyrosine), act as mediators of cell 
death due to enhanced levels of reactive oxygen species (formate), 
or simply be markers of vegetable intake (trimethylamine). These 
findings highlight the complexity of FGR pathogenesis and provide 
some clues that metabolic changes can take place as soon as 11 
weeks of gestation. Recently, Sulek and colleagues evaluated the 
metabolome of hair collected between 26 and 28 weeks from 41 
healthy pregnant women whose fetuses developed FGR (birth 
weight below the 10th percentile for gestational age) and 42 women 
whose fetuses had adequate birthweight for gestational age. Thirty-
two discriminatory metabolites were found, mostly AAs and fatty 
acids. Five of these metabolites composed a predictive model, 
which showed an extremely high AUC of 0.998 (22). However, the 
most severe cases of FGR can be diagnosed as early at 26 weeks 
of pregnancy, and perhaps 26–28 weeks would not be a suitable 
interval to screen for FGR in some women.
FGR has a multifactorial etiology, apparently resulting from the 
interaction between a complex biochemical profile and impaired 
placental perfusion, which negatively impacts the function of 
transporting nutrients. The knowledge of metabolism for this 
condition is still scarce. Therefore, metabolomics could contribute 
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to a better understanding of the pathophysiology of FGR and to 
a more precise definition of this syndrome. An early detection of 
fetuses at a higher risk for truly pathological growth restriction or a 
diagnosis of FGR among pregnant women could improve perinatal 
outcomes if appropriate interventions can be implemented during 
prenatal care.
Pregnancy hypertensive disorders
Preeclampsia (PE) is still a challenging condition in obstetrics 
practice, involving different clinical manifestations (i.e., early- and 
late-onset PE) that share the physiopathological aspect of inadequate 
trophoblast invasion of the maternal vasculature early in pregnancy. 
There are already known clinical (66) and ultrasonographic risk 
factors (67): the former can be identified at booking, and the latter 
can be better screened at the 2nd trimester (uterine artery waveform). 
Although easily and almost universally accessible, the strongest 
clinical risk factor history of preeclampsia cannot be applied to 
nulliparous women, which is a target group for PE (68). In addition, 
the good performance of uterine artery Doppler velocimetry 
requires availability of equipment and operator expertise (69). 
Therefore, great effort has been made to identify biomarkers that 
could be applied to diagnostic, prediction, or prognostic factors 
(i.e., soluble endoglin, PIGF and pregnancy-associated plasma 
protein-A PAPP-A) (70). However, these biomarkers still are not 
fully and easily available for clinical practice and some of them 
can only be evaluated at the 2nd or 3rd trimester when there are few 
therapeutic alternatives for these women.
Considering poor placentation and systemic endothelial 
activation in PE (71), some authors have been searching for 
metabolites that could explain the pathogenesis of the disease. 
Kenny et al. found increased levels of uric acid, which is related 
to ischemic conditions, and 2-oxoglutarate, or α-ketoglutaric acid, 
an intermediate of the citric acid cycle (or tricarboxylic acid cycle), 
which is increased with limited oxidative capacity (72). These 
metabolites could reinforce the hypothesis of placental hypoxia 
in preeclampsia, and low levels of taurine could be a marker of 
defective trophoblast invasion in early-onset PE (71,73).
It is interesting to note that alanine and glutamic acid levels are 
increased in women already diagnosed with PE (72) and early in 
pregnancy (74). Both alanine and glutamic acid are nonessential 
AAs and neurotransmitters. It seems that α-glutamate excitatory 
effects play an important role in membrane depolarization observed 
in epileptic seizures (75), which sheds light on the understanding 
of eclampsia. Alanine represents the main muscle energy source 
and has an inhibitory action in the brain, as does taurine (75). Renal 
function may also be affected in PE (76), and augmented levels of 
creatinine have been observed, either in the 1st (77) or in the 3rd 
trimester (72).
Omics studies have found many metabolic disturbances 
in preeclamptic women, such as disorders in carnitine, AAs, 
carbohydrate or fatty acid pathways, by diverse platforms. 
However, the available studies have used small sample sizes and 
do not control for pregnancy complications, such as SGA infants 
(78), fetal malformations or PTB (31), which can also show 
metabolic profile alterations. Additionally, it would be enlightening 
if longitudinal studies could perform data collection at different 
gestational ages.
On the other hand, it is notable that the AUC, sensitivity, and 
specificity of predicting early or late PE (71,77) can be improved 
when regression models mix metabolites with clinical factors, 
including weight, ethnicity, and mean arterial blood pressure. A 
first-trimester predictive model that showed promising results, with 
an AUC of 0.835 in a validation study, enrolled 50 women with 
early preeclampsia and 108 matched controls (79), which is still a 
modest number of participants. Therefore, it is fundamental, in the 
near future, to perform a study involving a heterogeneous group of 
nulliparous low-risk pregnant women, taking into account that this 
is the set with the highest risk of preeclampsia. The understanding 
of the metabolome profile of preeclampsia may contribute not only 
to prediction but also to improving the knowledge regarding cellular 
and molecular pathophysiology, providing better management 
of preeclampsia and, ultimately, better maternal and perinatal 
outcomes.
Gestational diabetes mellitus
Gestational diabetes mellitus (GDM) is diabetes that is first 
diagnosed in the second or third trimester of pregnancy that is not 
clearly either preexisting type 1 or type 2 diabetes, according to 
the American Diabetes Association (80). It is related to important 
maternal, fetal, and neonatal outcomes and is a high-risk factor 
for diabetes mellitus later in life (80). There are still controversies 
regarding diagnostic criteria, treatment and monitoring of GDM, 
but recent advances in omics studies can provide clues about 
the maternal metabolic profile in normal and diabetic affected 
pregnancies and may be helpful in understanding and predicting 
the disease.
Normal pregnancy is characterized by progressive insulin 
resistance (81) and increased levels of lipoproteins and lipoprotein-
cholesterol (82), and both phenomena increase glucose levels. Fat 
stores can be used as an energy source by the mother, so glucose 
can reach the fetus, which is the main energy source of the fetal 
unit and is easily transported through the placenta by facilitated 
diffusion (81,82). GDM, however, seems to promote a shift from 
gluconeogenesis to ketone body production, which is probably why 
fasting acylcarnitine ester levels are lower and 3-hydroxybutyrate 
are higher in diabetic compared to normal pregnancies (83).
In urine samples of 2nd-trimester diabetic pregnancies, Diaz 
et al. (2011) found increased levels of 2-hydroxyisobutyrate (43). 
This observation reinforces the association between GDM and 
type 2 diabetes (81), since this biomarker has also been identified 
in diabetic patients, reflecting disturbances in free fatty acid 
metabolism (84). Urinary excretion of 3-hydroxyisovalerate also 
appears to be increased in GDM (43) and reflects the reduced 
activity of β-methylcrotonyl-CoA carboxylase, a biotin-dependent 
enzyme (85). It is important to consider the (1) relationship between 
previous diabetes and congenital malformation (80) and (2) the 
possible teratogenic effect of biotin deficiency (85). This finding 
requires further investigation and may be helpful to improve the 
diagnostic criteria and follow-up of GDM.
Using proton nuclear magnetic resonance (1H-NMR) 
spectroscopy to study urine samples of 1st and 2nd-trimester 
pregnancies, Sachse et al. (2012) have shown that urine citrate 
increases with higher degrees of hyperglycemia (86). However, 
they did not find any difference in the metabolomic profile between 
normal and affected women, regardless of the diagnostic criteria of 
GDM, even after normalizing the results to the creatinine level or 
considering that the urine metabolomic profile is influenced by the 
immediate lifestyle and diet and less by the genetic background. 
On the other hand, UPLC-MS identified slightly increased levels of 
choline in urine in the 2nd trimester of prediagnostic GDM women 
(31). However, as choline was also altered in fetal malformations 
and plays a role in fetal brain development, it seems to be nonspecific 
for GDM (43).
Hair metabolomics was also investigated as a potential marker 
for GDM. Baker and colleagues analyzed hair metabolites in two 
different cohorts using samples of women who developed GDM 
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matched by BMI to controls with uncomplicated pregnancies. 
Analyzing hair samples collected at the time of oral glucose 
tolerance testing (24-28 weeks of gestation) of 47 Chinese 
women in each group, the authors found one metabolite (adipic 
acid) that differs significantly between groups and might be 
potential discriminatory (87). Using hair samples collected earlier 
in pregnancy (at 20 weeks) of women who participated in the 
SCOPE study, two metabolites (itaconic acid and cis-aconitate) had 
significantly different levels between groups (20 women with GDM 
and 26 controls) (88). Although the results are from pilot studies, 
new potential approaches demand investigations in larger datasets.
Studies have used various metabolomic technologies, in either 
AF, maternal plasma, serum, hair, or urine samples, at various times 
during pregnancy. Each technique and biological sample has distinct 
properties of sensitivity, specificity, and power to detect metabolic 
changes that affect GDM, and findings are still inconclusive (89). 
A comprehensive overview of this condition could be approached 
by studies involving several biological fluids in different gestational 
ages and taking into account dietary intake and treatment options 
(89). GDM is a worldwide problem, and its assessment during 
pregnancy can improve gestational and perinatal outcomes. More 
research is needed to identify metabolites that could be used as 
biomarkers of disease and to better define this condition.
 ■ Maternal and fetal infections
Metabolomics has also been used for translational research in 
infectious diseases during pregnancy. The possibility of identifying 
a pattern of metabolites related to the more severe condition or to the 
development of fetal/neonatal sequelae, confirming a maternal-fetal 
transmission and recognizing potential pathological conditions of 
the fetus is a worthy approach, especially when current diagnostics 
tests are not sufficiently sensitive and specific. The current spread of 
Zika virus infection is a very recent example of how challenging the 
identification of pathophysiological mechanisms and the creation 
of reliable serological tests in some infectious diseases can be. The 
laboratory testing for Zika virus infection guidelines of the WHO 
demonstrates the difficulty in confirming maternal infection for 
suspected cases with more than one week after onset of symptoms or 
with a fetal diagnosis of neurological impairment in asymptomatic 
women (90). The CDC diagnostic testing recommendations 
highlight the common cross-reaction with other related flaviviruses, 
such as dengue, chikungunya, and yellow fever viruses (91), calling 
attention to the importance of more reliable tests.
Recently, Zhou and colleagues demonstrated dynamic changes 
in the metabolomic profile of mice during Toxoplasma gondii 
infection (92). The authors showed that a set of metabolites could 
discriminate infected samples from controls, showing an AUC of 
0.996. Fanos and colleagues conducted a metabolomic approach 
using urinary samples of newborns infected by cytomegalovirus 
and controls (10). The preliminary investigation showed that the 
abundance of a set of metabolites was significantly different between 
the groups. Various studies related to nonpregnancy infections, 
such as Haemophilus influenzae, dengue, malaria, tuberculosis, 
and Clostridium difficile, have already demonstrated the potential 
contribution of metabolomics to the pathogenesis, mechanisms of 
adaptation, severity, host response and impairment (93-96).
Another potential applicability for metabolomic studies 
is chorioamnionitis, an infection that can present not only as a 
subclinical condition with minimum consequences for women or 
fetuses/newborns but also as a severe infection leading to sepsis and 
severe maternal and neonatal morbidity and mortality (97-101). 
Chorioamnionitis is a major cause of mortality in many countries 
and lacks reliable markers for early diagnosis (97,102,103). For 
instance, women with PROM, especially if preterm, are at higher 
risk for infection, and currently available markers collected from 
blood, vaginal secretions or AF have not proven to be highly 
accurate in the prediction or early diagnosis of chorioamnionitis 
(97,102,104-108). In this case, a false positive test for infection 
can lead to unnecessary interventions, such as prematurity, and a 
false negative test might determine the development of neonatal 
sepsis. Therefore, not only a timely identification of infection but 
a more accurate diagnosis is crucial to prevent severe adverse 
outcomes.
A few metabolomic studies have been conducted to address 
the early identification of women with amniotic infection. A 
metabolomic analysis of AF from 40 women with rupture of 
membranes or preterm labor was performed, and the results were 
compared according to the microbiological/histological status 
of infection and neonatal outcomes (infection and perinatal brain 
injury) (109). Several metabolites of more than 8 metabolic 
pathways were identified as potential markers of chorioamnionitis. 
The sphingolipid metabolic pathway was the most important group 
of metabolites, showing the strongest discriminant power with 
an AUC of >0.99% and >0.95% to discriminate cases with and 
without brain injuries in chorioamnionitis cases, respectively. The 
authors presented a set of metabolites as potential best biomarker 
candidates, discussing many possible correlations and underlying 
mechanisms related to chorioamnionitis. However, they also 
clarified that the external validation of findings is limited due to the 
use of specific methodology, excluding some phenotypes of women 
and newborns to create a more homogenous comparison analysis. 
According to the authors, this homogeneity of outcomes is not what 
is found “in real life”.
A study from Romero and colleagues also demonstrated that 
metabolomic profiling is useful for discriminating cases of preterm 
delivery with and without intra-amniotic infection (42). Another 
case-control study, this time using lipidomic analysis of the AF, also 
identified potential markers for amniotic infection (110,111). Both 
findings still require further validation.
Metabolomic studies assessing potential makers for 
chorioamnionitis usually use AF samples collected after the 
rupturing of membranes through amniocentesis in sites where 
this invasive procedure is generally standard to address amniotic 
infection. The AF is a key tissue for maternal and perinatal 
research, considering its interactions with the placenta, mother, 
and fetal tissues, providing RNA, DNA and metabolites of all three 
components (24,112). Nevertheless, more studies using blood, 
urine, hair, or vaginal secretion markers might be important to 
develop a more reproducible and less invasive method to investigate 
chorioamnionitis.
Severe maternal morbidity and other conditions
Maternal complications during pregnancy, childbirth and 
postpartum periods are part of a continuum or spectrum of 
morbidity classified from mild to severe. Depending on the severity, 
the morbidity can be potentially life-threatening and put women 
at risk for “maternal near miss” or maternal death. Pragmatically, 
maternal near miss is defined as an experience of near death 
that can be identified considering aspects of clinical, laboratory 
and management-based criteria, according to the World Health 
Organization (113).
Delays in preventing, diagnosing, or treating maternal 
complications are related to poorer maternal outcomes (114). 
Therefore, the early identification of severe maternal morbidity 
might provide a window of opportunity to save mothers from short- 
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and long-term adverse outcomes. The main causes of maternal 
mortality are related to hemorrhage and hypertensive complications 
(101), followed by sepsis, abortion, embolism, and other indirect 
causes. Clinical tools are being studied to identify, measure, and 
monitor maternal morbidity (113,115,116). Ordinarily, the clinical 
tools are composed of maternal symptoms and signs and clinical 
support characteristics. This means that the diagnosis of maternal 
morbidity occurs in an advanced stage of severity. Despite being 
a great advance, the use of the definition of potentially life-
threatening conditions and maternal near miss would be even more 
useful to prevent maternal death and short- and long-term adverse 
consequences, with earlier diagnoses.
The clinical tool called the Sequential Organ Failure 
Assessment (SOFA) can be used to identify severe maternal 
morbidity. However, even this well-known and widely used tool 
demands a certain degree of organ dysfunction as a proxy for 
prediction. Metabolomic analyses could be an interesting approach 
to early identify severe maternal morbidity (life-threatening 
conditions and maternal near miss). The identification of common 
pathways of preclinical disorders related to maternal morbidity 
could be useful, widening the window of opportunity to act before 
severe organ dysfunction. Some studies have already described 
altered metabolomic profiles related to acute heart failure induced 
by shock, severe sepsis, and septic and hemorrhagic shock (117-
119). The results show that metabolomic profiles can discriminate 
degrees of severity and may be used for early diagnosis. Therefore, 
such profiles might be useful to predict organ failure or systemic 
inflammatory response syndrome in pregnant women as well, 
independent of the cause of morbidity.
Based on the same idea, the identification of a metabolomic 
pattern directly related to the main causes of severe maternal 
morbidity, hypertensive and hemorrhage disorders seems to 
be tangible. Aberrant placentation, for instance, is related to 
hypertensive and hemorrhagic complications during pregnancy. The 
abnormal remodeling of spiral arteries leads to ischemic placental 
disease mediated by many inflammatory, immunologic, and 
oxidative stress pathways (120,121). A discovery of metabolomic 
analyses using samples from women with potentially life-
threatening conditions, maternal near miss, and noncomplicated 
pregnancies might demonstrate whether it is possible to identify 
common metabolites related to maternal morbidity.
 ■ DISCUSSION
The 21st century has had remarkable innovations in technology, 
especially in service industries, such as communication and 
informatics involving smartphones and high-quality wireless 
networks, changing the way people live and interact. Modification is 
usually required by the need for new ways to deal with a competitive 
routine and a large amount of information in different parts of the 
globe, all of which is part of the new era of globalization phenomena. 
There is a classic theory about innovations and economic growth 
based on creative destruction (122). Briefly, one of the bases of this 
theory is the stationary state, which is the gap period between the 
development of new research and, consequently, new innovations. 
This state can lead to innovation mostly depending on the rate 
of interest and the number and impact of available innovations. 
Translating this concept to our area of interest, we could say that 
research on maternal and perinatal health urges innovation.
Maternal and child health are priority topics of the third 
sustainable development goal (2). Obstetric complications, such 
as PE, PTB, FGR, and GDM, have a major impact on maternal 
and perinatal health because they can lead to short- and long-
term consequences for women or newborns, from childhood to 
adulthood. Biological biomarkers seem to be essential for the 
development of predictive models because they play an important 
role in the pathophysiology, whether in cause or in consequence 
mechanisms. The integrated study of the biological interactions in 
an organism (systems biology) has led to omics-based research, 
which has been demonstrated to be a promising and useful approach 
to assess such complex syndromes (3,38). To yield reliable and 
reproducible information, samples must follow the specific and 
detailed methodology for processing and storage, and data on these 
details are key to allow comparisons between studies and advances 
in metabolomic research in maternal-fetal medicine.
Metabolomics seems to be the most reasonable approach to 
studying the majority of obstetrical syndromes, considering the 
costs, confounders, analytical techniques, output data generation 
and the possibility of addressing final pathways for the underlying 
mechanisms involved in the occurrence of each complication. 
Metabolomic studies have generated optimistic results so far, 
widening the opportunity to explore new methodologies for sample 
collection, preparation, and analysis. Apart from that, the technique 
requires validation of the initial findings of pilot studies in larger 
datasets, using numerous multiethnic population cohorts. Thus, 
metabolomics might be a sensible way to move forward in the 
prediction and prevention of maternal complications, achieving a 
significant impact on people’s lives as the 21st-century technology 
revolution may have done.
The current review aimed to present how metabolomics has 
become a promising approach for maternal and perinatal health 
research in recent years, showing (especially for a nonexpert audience) 
the rationale behind this high-technology method in the omics science 
perspective and its potential translational application. The main 
maternal complications during pregnancy, such as preeclampsia, 
PTB, FGR and GDM, have multifactor complex etiologies, and 
certainly, an expressive number of unknown underlying factors, but 
the pathways related to the occurrence of these complications are 
not yet clarified. Such complexity makes their prediction extremely 
challenging also considering that the pathophysiology might involve 
genetic and environmental adaptive mechanisms from maternal and 
fetal components. Metabolomics is the study of the metabolites in a 
given sample, and it is the closest correspondent to the cell, tissue 
or organism function compared to other omics sciences, such as 
genomics, transcriptomics or proteomics. Metabolomic studies of 
maternal complications during pregnancy can be a valuable method 
to explore biomarkers in different sources of samples, although 
advances in reproducible analytical procedures and external 
validations in larger datasets are still necessary.
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